Thursday, November 15, 2007
Back To Faculty Page: Print Current Session:
|
|
Thursday
SESSION XIV:
CRITICAL EVALUATION OF CAROTID ARTERY STENTING (CAS) (6-MINUTE TALKS)
Moderators:Peter Gaines, M.D. , Frank J. Veith, M.D.
|
|
SESSION XIV SCHEDULE | |
1:30 PM - 1:36 PM | CAS vs. CEA vs. Medical Treatment: How To Choose Without Bias |
Presenters(s): Michael R. Jaff, D.O. | |
1:37 PM - 1:43 PM | How To Pick By Duplex Ultrasonography Asymptomatic Patients Who Will Develop Symptoms And Who Need Treatment |
Presenters(s): Jose Fernandes e Fernandes, MD, PhD, FRCS (Eng), FACS | |
1:44 PM - 1:50 PM | Carotid Plaque Characteristics And Their Therapeutic And Prognostic Implications |
Presenters(s): Giorgio M. Biasi, M.D. | |
1:51 PM - 1:57 PM | CAS Is Emerging As Best And Safest When Carotid Intervention May Not Be Needed At All: Is CEA Now Best After All And Will This Change With Better Devices? |
Presenters(s): Frank J. Criado, M.D. | |
1:58 PM - 2:04 PM | Are Statins Indicated Before CEA: How Long Before Should They Be Started? |
Presenters(s): Bruce A. Perler, M.D., M.B.A. | |
2:05 PM - 2:11 PM | Statins Prevent Strokes: The SPARCLE Trial: Does It Render NASCET, ECST, ACAS, ACST Obsolete And Mandate New Trials Of Best Medical Treatment Versus CEA And CAS? |
Presenters(s): Henrik Sillesen, MD, DMSc | |
2:12 PM - 2:18 PM | What Lesion Characteristics Are Associated With Increased Risk Of Stroke With CAS: Long Lesions Are Dangerous |
Presenters(s): Michel S. Makaroun, M.D. / Mark H. Wholey, M.D. | |
2:19 PM - 2:25 PM | CAS Can Be Done Without Cerebral Embolic Protection: How Can This Be Done Safely? |
Presenters(s): Franco Perona, M.D. | |
2:26 PM - 2:32 PM | Strategies For Avoiding Embolic And Non-Embolic Stroke With CAS: How To Choose An Embolic Protection Device |
Presenters(s): Sumaira Macdonald, MBChB (Comm), FRCP, FRCR, PhD | |
2:33 PM - 2:40 PM | Panel Discussion |
Moderator(s): Jean-Pierre Becquemin, M.D., F.R.C.S. / Keith D. Calligaro, M.D. | |
2:40 PM - 2:46 PM | Debate: CAS Is Currently Being Underutilized Viz A Viz Medical Treatment And CEA: Reflections On CAS By A Master Who Has Done More Than 1,000 |
Presenters(s): Mark H. Wholey, M.D. | |
2:47 PM - 2:53 PM | Debate: CAS Is Currently Being Overutilized Viz A Viz Medical Treatment And CEA |
Presenters(s): Peter R.F. Bell, M.D., F.R.C.S., D.S.C., K.B.E. | |
2:54 PM - 3:00 PM | Update On The German SPACE Trial: One Year Outcome Results With Subgroup Analysis: CEA vs. CAS In Symptomatic Patients |
Presenters(s): Hans-Henning Eckstein, M.D., Ph.D. | |
3:01 PM - 3:07 PM | The EVA-3S Trial Was Flawed Because The Interventionists Were Inexperienced And Not Representative Of The Best: One Participant’s View |
Presenters(s): Max Amor, M.D. | |
3:08 PM - 3:14 PM | The EVA-3S Trial Was Not Flawed Because The Interventionists Were State-Of-The-Art And Got Better Outcomes In Symptomatic Patients Than In The CAPTURE Trial: What Conclusion Should We Reach: The View Of Other Participants |
Presenters(s): Jean Michel Bartoli, M.D. / Philippe Piquet, M.D. | |
3:15 PM - 3:21 PM | Most Strokes Following CAS Occur After Embolic Protection Is Over: EVA-3S Was Not Flawed: Another Participant’s View |
Presenters(s): Emmanuel M. Houdart, M.D. | |
3:22 PM - 3:28 PM | Do We Need A Trial Comparing Current Best Medical Therapy Against CEA And CAS: What Is The Status Of The TACIT Trial: Will It Ever Happen? |
Presenters(s): John H. Rundback, M.D., F.S.I.R., F.A.H.A. | |
3:29 PM - 3:38 PM | Panel Discussion |
END OF SESSION XIV |